- Home
- GMAB vs FLEX Comparison
GMAB vs FLEX Comparison
Compare GMAB & FLEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- FLEX
- Stock Information
- Founded
- GMAB 1999
- FLEX 1990
- Country
- GMAB Denmark
- FLEX United States
- Employees
- GMAB N/A
- FLEX N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- FLEX Electrical Products
- Sector
- GMAB Health Care
- FLEX Technology
- Exchange
- GMAB Nasdaq
- FLEX Nasdaq
- Market Cap
- GMAB 15.0B
- FLEX 13.7B
- IPO Year
- GMAB N/A
- FLEX 1994
- Fundamental
- Price
- GMAB $20.45
- FLEX $39.83
- Analyst Decision
- GMAB Buy
- FLEX Strong Buy
- Analyst Count
- GMAB 8
- FLEX 6
- Target Price
- GMAB $43.00
- FLEX $40.83
- AVG Volume (30 Days)
- GMAB 1.5M
- FLEX 3.2M
- Earning Date
- GMAB 11-06-2024
- FLEX 10-30-2024
- Dividend Yield
- GMAB N/A
- FLEX N/A
- EPS Growth
- GMAB 14.35
- FLEX 30.53
- EPS
- GMAB 10.80
- FLEX 2.26
- Revenue
- GMAB $2,967,926,227.00
- FLEX $25,449,000,000.00
- Revenue This Year
- GMAB $30.31
- FLEX N/A
- Revenue Next Year
- GMAB $16.49
- FLEX $5.26
- P/E Ratio
- GMAB $18.39
- FLEX $17.64
- Revenue Growth
- GMAB 17.75
- FLEX N/A
- 52 Week Low
- GMAB $20.37
- FLEX $18.80
- 52 Week High
- GMAB $32.88
- FLEX $40.48
- Technical
- Relative Strength Index (RSI)
- GMAB 25.28
- FLEX 67.23
- Support Level
- GMAB $20.50
- FLEX $36.56
- Resistance Level
- GMAB $23.47
- FLEX $40.30
- Average True Range (ATR)
- GMAB 0.45
- FLEX 1.07
- MACD
- GMAB -0.18
- FLEX -0.03
- Stochastic Oscillator
- GMAB 2.74
- FLEX 88.33
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About FLEX Flex Ltd.
Flex Ltd is a contract manufacturing company providing comprehensive electronics design, manufacturing, and product management services to electronics and technology companies. The company's operating segments include Flex Agility Solutions (FAS) and Flex Reliability Solutions (FRS). Flex Agility Solutions segment includes markets such as Communications, Enterprise and Cloud; Lifestyle; and Consumer Devices. Flex Reliability Solutions segment includes markets such as Automotive, Health Solutions, and Industrial.